Cargando…
Insight Into the Prospects for RNAi Therapy of Cancer
RNA interference (RNAi), also known as gene silencing, is a biological process that prevents gene expression in certain diseases such as cancer. It can be used to improve the accuracy, efficiency, and stability of treatments, particularly genetic therapies. However, challenges such as delivery of ol...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007863/ https://www.ncbi.nlm.nih.gov/pubmed/33796026 http://dx.doi.org/10.3389/fphar.2021.644718 |
_version_ | 1783672578332688384 |
---|---|
author | Tian, Zhili Liang, Guohui Cui, Kunli Liang, Yayu Wang, Qun Lv, Shuangyu Cheng, Xiaoxia Zhang, Lei |
author_facet | Tian, Zhili Liang, Guohui Cui, Kunli Liang, Yayu Wang, Qun Lv, Shuangyu Cheng, Xiaoxia Zhang, Lei |
author_sort | Tian, Zhili |
collection | PubMed |
description | RNA interference (RNAi), also known as gene silencing, is a biological process that prevents gene expression in certain diseases such as cancer. It can be used to improve the accuracy, efficiency, and stability of treatments, particularly genetic therapies. However, challenges such as delivery of oligonucleotide drug to less accessible parts of the body and the high incidence of toxic side effects are encountered. It is therefore imperative to improve their delivery to target sites and reduce their harmful effects on noncancerous cells to harness their full potential. In this study, the role of RNAi in the treatment of COVID-19, the novel coronavirus disease plaguing many countries, has been discussed. This review aims to ascertain the mechanism and application of RNAi and explore the current challenges of RNAi therapy by identifying some of the cancer delivery systems and providing drug information for their improvement. It is worth mentioning that delivery systems such as lipid-based delivery systems and exosomes have revolutionized RNAi therapy by reducing their immunogenicity and improving their cellular affinity. A deeper understanding of the mechanism and challenges associated with RNAi in cancer therapy can provide new insights into RNAi drug development. |
format | Online Article Text |
id | pubmed-8007863 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80078632021-03-31 Insight Into the Prospects for RNAi Therapy of Cancer Tian, Zhili Liang, Guohui Cui, Kunli Liang, Yayu Wang, Qun Lv, Shuangyu Cheng, Xiaoxia Zhang, Lei Front Pharmacol Pharmacology RNA interference (RNAi), also known as gene silencing, is a biological process that prevents gene expression in certain diseases such as cancer. It can be used to improve the accuracy, efficiency, and stability of treatments, particularly genetic therapies. However, challenges such as delivery of oligonucleotide drug to less accessible parts of the body and the high incidence of toxic side effects are encountered. It is therefore imperative to improve their delivery to target sites and reduce their harmful effects on noncancerous cells to harness their full potential. In this study, the role of RNAi in the treatment of COVID-19, the novel coronavirus disease plaguing many countries, has been discussed. This review aims to ascertain the mechanism and application of RNAi and explore the current challenges of RNAi therapy by identifying some of the cancer delivery systems and providing drug information for their improvement. It is worth mentioning that delivery systems such as lipid-based delivery systems and exosomes have revolutionized RNAi therapy by reducing their immunogenicity and improving their cellular affinity. A deeper understanding of the mechanism and challenges associated with RNAi in cancer therapy can provide new insights into RNAi drug development. Frontiers Media S.A. 2021-03-16 /pmc/articles/PMC8007863/ /pubmed/33796026 http://dx.doi.org/10.3389/fphar.2021.644718 Text en Copyright © 2021 Tian, Liang, Cui, Liang, Wang, Lv, Cheng and Zhang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Tian, Zhili Liang, Guohui Cui, Kunli Liang, Yayu Wang, Qun Lv, Shuangyu Cheng, Xiaoxia Zhang, Lei Insight Into the Prospects for RNAi Therapy of Cancer |
title | Insight Into the Prospects for RNAi Therapy of Cancer |
title_full | Insight Into the Prospects for RNAi Therapy of Cancer |
title_fullStr | Insight Into the Prospects for RNAi Therapy of Cancer |
title_full_unstemmed | Insight Into the Prospects for RNAi Therapy of Cancer |
title_short | Insight Into the Prospects for RNAi Therapy of Cancer |
title_sort | insight into the prospects for rnai therapy of cancer |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007863/ https://www.ncbi.nlm.nih.gov/pubmed/33796026 http://dx.doi.org/10.3389/fphar.2021.644718 |
work_keys_str_mv | AT tianzhili insightintotheprospectsforrnaitherapyofcancer AT liangguohui insightintotheprospectsforrnaitherapyofcancer AT cuikunli insightintotheprospectsforrnaitherapyofcancer AT liangyayu insightintotheprospectsforrnaitherapyofcancer AT wangqun insightintotheprospectsforrnaitherapyofcancer AT lvshuangyu insightintotheprospectsforrnaitherapyofcancer AT chengxiaoxia insightintotheprospectsforrnaitherapyofcancer AT zhanglei insightintotheprospectsforrnaitherapyofcancer |